MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions
NCT ID: NCT02400632
Last Updated: 2020-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
60 participants
INTERVENTIONAL
2015-06-30
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon
NCT03913832
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels
NCT04893291
AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease
NCT05471245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MAGIC-TOUCH Drug-eluting balloon
in-stent restenosis treated with drug-eluting balloon
MAGIC-TOUCH Drug-eluting Balloon
in-stent restenosis treated with drug eluting balloon
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MAGIC-TOUCH Drug-eluting Balloon
in-stent restenosis treated with drug eluting balloon
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Symptomatic ischemic heart disease;
3. Acceptable candidate for Coronary Artery Bypass Graft (CABG) or Angioplasty;
4. Target lesion located in a native coronary artery
5. Target lesion (maximum length is 15 mm by visual estimate) covered by a single balloon;
6. Reference vessel diameter must be ≥3.0 to ≤ 3.5 mm by visual estimate;
7. Target lesion ≥50% and \<100% stenosed by visual estimate
8. Restenosis of initially stented main vessel.
Exclusion Criteria
2. Patient has had a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure;
3. Lesions in bypass grafts or bifurcations
4. Any non-target vessel or lesion intended to be treated during the index procedure, which is an unprotected left main, ostial lesion, chronic total occlusion (CTO), heavily calcified, bifurcation, vein grafts, have angiographic evidence of thrombus, be anything requiring atherectomy, thrombectomy, or pre-treatment with anything other than balloon angioplasty;
5. Patient presents with cardiogenic shock;
6. Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion
7. Unprotected left main coronary artery disease with ≥50% stenosis;
8. Totally occluded target vessel (TIMI flow 0);
9. Calcified target lesion(s) which cannot be successfully pre-dilated;
10. A significant (\>50%) stenosis proximal or distal to the target lesion that cannot be covered by same single balloon
11. Diffuse distal disease to target lesion with impaired runoff;
12. Left ventricular ejection fraction (LVEF) ≤30% (LVEF must be obtained within 1 months prior to the index procedure).
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Scitech Produtos Medicos Ltda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandre Abizaid, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto Dante Pazzanese de Cardiologia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Bandeirantes
São Paulo, São Paulo, Brazil
Instituto Dante Pazzanese de Cardiologia
São Paulo, São Paulo, Brazil
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAGIC TOUCH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.